| 1 |
NCT01174914 |
Completed |
Effectiveness Study Low-Dose Naltrexone Versus ARV's for HIV+ |
|
- Other: ARV's + Placebo
- Drug: Naltrexone
- Drug: Naltrexone + ARV's
|
Interventional
|
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Prevention
|
- CD4+ percentage (change in HIV-1 seropositive patients)
- Clinical assessment of evidence of AIDS or other serious illness
|
171 |
All |
18 Years to 60 Years (Adult) |
NCT01174914 |
TOFLDNMALIHIVb |
|
March 2008 |
March 2010 |
March 2010 |
August 4, 2010 |
August 4, 2010 |
|
- University Hospital of Point G
Bamako, Mali
|
|
| 2 |
NCT01184456 |
Unknown † |
A Controlled Trial to Evaluate the Effects of GanedenBC30 on the Immune System |
- HIV Infection
- Gastrointestinal Symptoms
|
- Dietary Supplement: GanedenBC30, GBI-30, PTA-6086
- Drug: Placebo
|
Interventional
|
Phase 2 |
- AIDS Healthcare Foundation
- Ganeden Biotech, Inc.
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Safety
- Improvement in CD4 cell counts.
- Improvement of gastrointestinal symptoms.
|
24 |
All |
18 Years and older (Adult, Older Adult) |
NCT01184456 |
AHF-GAN01 |
|
August 2010 |
July 2011 |
July 2011 |
August 19, 2010 |
August 19, 2010 |
|
- AHF Research Center
Beverly Hills, California, United States
|
|
| 3 |
NCT01187979 |
Completed |
Reducing HIV in Adolescents |
|
- Behavioral: Cash incentives
- Behavioral: Life skills curriculum
|
Interventional
|
Phase 2 |
- Centre for the AIDS Programme of Research in South Africa
- MIET Africa
- KwaZulu-Natal Department of Education
- Embassy of the Kingdom of the Netherlands (EKN)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- HIV-incidence rates
- Academic performance measured as an overall passing grade (50%)
- voluntary uptake of HIV testing
- (and 5 more...)
|
3217 |
All |
13 Years and older (Child, Adult, Older Adult) |
NCT01187979 |
CAPRISA 007 |
RHIVA |
September 2010 |
August 2014 |
August 2014 |
August 25, 2010 |
January 19, 2017 |
|
- Vulindlela Clinical Research Site
Durban, KwaZulu-Natal, South Africa
|
|
| 4 |
NCT01186042 |
Completed |
Chronic HIV Infection and Aging in NeuroAIDS (CHAIN) |
|
|
Observational
|
|
- University of Nebraska
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Cross-Sectional
|
- Evaluate the feasibility of enrolling older HIV-infected patients and younger controls into a prospective, observational study.
- Selection of the optimal test battery to measure the areas of interest
- Participant acceptance of the measures involved
- Preliminary data collection to inform the size and design of a larger, follow-up study.
|
21 |
All |
20 Years to 75 Years (Adult, Older Adult) |
NCT01186042 |
396-10-FB
P30MH062261 |
CHAIN |
August 2010 |
December 17, 2014 |
December 17, 2014 |
August 20, 2010 |
September 11, 2017 |
|
- University of Nebraska Medical Center
Omaha, Nebraska, United States
|
|
| 5 |
NCT01173510 |
Withdrawn |
A Pilot Study to Determine if Raltegravir Eradicates HIV From Peripheral Blood Mononuclear Cells |
- HIV Infections
- Acquired Immune Deficiency Syndrome
|
- Drug: Raltegravir plus Truvada
- Drug: Atripla
|
Interventional
|
Phase 4 |
- Community Research Initiative of New England
- Merck Sharp & Dohme Corp.
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Efficacy in eradicated HIV-1 integrated DNA from PBMCs
- Efficacy in eradicating HIV-1 integrated DNA from CD34+ cells
- Efficacy in eradicating PBMC-associated early viral spliced mRNA
- (and 3 more...)
|
0 |
All |
18 Years and older (Adult, Older Adult) |
NCT01173510 |
10-184 |
|
August 23, 2010 |
October 19, 2012 |
October 19, 2012 |
August 2, 2010 |
June 14, 2017 |
|
|
|
| 6 |
NCT01196195 |
Completed |
KONCERT A Kaletra ONCE Daily Randomised Trial of the Pharmacokinetics, Safety and Efficacy of Twice-daily Versus Once-daily Lopinavir/Ritonavir Tablets Dosed by Weight as Part of Combination Antiretroviral Therapy in Human Immunodeficiency Virus-1 (HIV-1) Infected Children (PENTA 18) |
- Antiretroviral Therapy in HIV-1 Infected Children
|
- Drug: Kaletra dosed once daily
- Drug: kaletra dosed twice daily
|
Interventional
|
Phase 2
Phase 3 |
- PENTA Foundation
- Medical Research Council
- French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological suppression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).
- To compare the pharmacokinetics of twice-daily lopinavir/ritonavir tablets with once-daily dosing in the same children
- To evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological suppression. This is measured by HIV-1 RNA <400/<50 copies/ml.
- Acceptability and adherence to once-daily versus twice-daily dosing of lopinavir/ritonavir tablets
|
173 |
All |
up to 18 Years (Child, Adult) |
NCT01196195 |
KONCERT protocol, version 1.6
2009-013648-35 |
KONCERT |
August 2010 |
July 2012 |
August 2013 |
September 8, 2010 |
October 28, 2013 |
|
- Charite University Hospital Berlin
Berlin, Germany - Department of Pediatric Oncology Hematology and Immunology KA02
Dusseldorf, Germany - J W Goethe University
Frankfurt, Germany - (and 14 more...)
|
|
| 7 |
NCT01171495 |
Completed |
Impact of Nutrition Intervention on HIV/AIDS Infected Patients |
- Human Immunodeficiency Virus (HIV)
- Acquired Immune Deficiency Syndrome (AIDS)
|
- Dietary Supplement: Theragran-M; Ensure Plus
- Dietary Supplement: Theragran-M
|
Interventional
|
Phase 3 |
- Caribbean Health Research Council
- The University of The West Indies
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Effects of nutritional intervention on anthropometry in HIV infected individuals.
- Effects of nutritional intervention on the clinical and immune status in HIV infected individuals.
|
121 |
All |
18 Years to 50 Years (Adult) |
NCT01171495 |
CHRC 51016 |
INI |
April 2008 |
August 2009 |
August 2009 |
July 28, 2010 |
July 28, 2010 |
|
- Comprehensive Health Centre
Kingston, Jamaica
|
|
| 8 |
NCT01188941 |
Completed |
Linkage and Retention: A Randomized Trial to Optimize HIV/TB Care in South Africa |
|
- Behavioral: Health System Navigator
|
Interventional
|
Not Applicable |
- Massachusetts General Hospital
- National Institutes of Health (NIH)
- National Institute of Mental Health (NIMH)
- (and 5 more...)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Health Services Research
|
- Linkage and Retention in Care: ART-eligible Patients
- Linkage and Retention in Care: TB Patients
- Linkage and Retention in Care: ART-eligible HIV/TB Co-infected Patients
|
1899 |
All |
18 Years and older (Adult, Older Adult) |
NCT01188941 |
2006-P-001379/26
R01MH090326 |
Sizanani |
August 2010 |
April 2014 |
April 2015 |
August 26, 2010 |
April 19, 2017 |
|
- St. Mary's Hospital
Durban, KwaZulu-Natal, South Africa - McCord Hospital
Durban, KwaZulu-Natal, South Africa - Mariannridge Clinic
Durban, KwaZulu-Natal, South Africa - Tshelimnyama Clinic
Durban, KwaZulu-Natal, South Africa
|
|
| 9 |
NCT01177995 |
Completed |
Russian Labor Migrant HIV Prevention Trial |
|
- Behavioral: Social Network Intervention
|
Interventional
|
Phase 2 |
- Medical College of Wisconsin
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Unprotected sexual intercourse events with a nonspousal partner
- AIDS-related knowledge, attitudes, intentions, perceived norms, and self-efficacy
- Substance use related to sexual behavior
|
207 |
All |
16 Years and older (Child, Adult, Older Adult) |
NCT01177995 |
R24MH082471
PRO9948 |
|
October 2008 |
September 2011 |
August 2013 |
August 9, 2010 |
August 23, 2013 |
|
|
|
| 10 |
NCT01172535 |
Completed
Has Results |
A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the WHO Pediatric Weight Band Dosing Guidelines |
|
- Drug: Lopinavir/ritonavir
|
Interventional
|
Phase 2
Phase 3 |
- National Institute of Allergy and Infectious Diseases (NIAID)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Lopinovir/Ritonavir Area Under the Concentration-time Curve (AUC0-24)
- Maximum Concentration of Lopinavir/Ritonavir (Cmax)
- Minimum Concentration of Lopinavir/Ritonavir (Cmin)
- (and 7 more...)
|
97 |
All |
Child, Adult, Older Adult |
NCT01172535 |
P1083
10787
IMPAACT P1083 |
|
November 2010 |
December 2013 |
December 2013 |
July 29, 2010 |
December 21, 2015 |
December 21, 2015 |
- University of California, UC San Diego CRS
La Jolla,, California, United States - Univ. of Colorado Denver NICHD CRS
Aurora, Colorado, United States - Boston Medical Center Ped. HIV Program NICHD CRS
Boston, Massachusetts, United States - (and 16 more...)
|
|
| 11 |
NCT01185028 |
Completed
Has Results |
A Safety and Tolerability Study of Nitazoxanide in HIV-HCV Treatment Failures |
- Hepatitis C Infection
- HIV Infection
|
- Drug: Nitazoxanide With Pegylated Interferon And Ribavirin
|
Interventional
|
Phase 1
Phase 2 |
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants With Adverse Events
- Sustained Viral Response Rate
- Tolerability
|
8 |
All |
18 Years and older (Adult, Older Adult) |
NCT01185028 |
100183
10-CC-0183 |
|
August 2010 |
October 2011 |
October 2011 |
August 19, 2010 |
March 21, 2018 |
May 15, 2013 |
- Family Medical and Counseling Services, SE
Washington, District of Columbia, United States - Unity Health Care/Walker Jones, NE
Washington, District of Columbia, United States - Whitman Walker Clinic, NW
Washington, District of Columbia, United States - National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
|
| 12 |
NCT01378156 |
Completed |
A Safety and Immunogenicity Study of a Plasmid DNA Prime and MVA Boost Vaccine in HIV-1 Infected Adults on ART |
|
- Biological: JS7 plasmid DNA and MVA62B vaccine
|
Interventional
|
Phase 1 |
- GeoVax, Inc.
- AIDS Research Consortium of Atlanta
- University of Alabama at Birmingham
- AIDS Research Alliance
|
Industry / Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety in all phases of study.
- Immunogenicity
|
9 |
All |
18 Years to 50 Years (Adult) |
NCT01378156 |
GV-TH-01 |
|
June 2010 |
May 2014 |
May 2014 |
June 22, 2011 |
November 14, 2017 |
|
- The University of Alabama at Birmingham Alabama Vaccine Research Clinic
Birmingham, Alabama, United States - AIDS Research Alliance
Los Angeles, California, United States - AIDS Research Consortium of Atlanta
Atlanta, Georgia, United States
|
|
| 13 |
NCT01180075 |
Completed |
Tenofovir, Emtricitabine, Efavirenz and Atazanavir Pharmacokinetics in the Aging HIV-Infected Population |
- Human Immunodeficiency Virus
|
- Drug: tenofovir/emtricitabine/efavirenz (TDF/FTC/EFV)
- Drug: tenofovir/emtricitabine (TDF/FTC)
- Drug: Atazanavir (ATV)
- (and 2 more...)
|
Observational
|
|
- University of North Carolina, Chapel Hill
- National Institute of Allergy and Infectious Diseases (NIAID)
|
Other / NIH |
- Time Perspective: Prospective
|
- Clearance estimates for each drug, adjusted for age and frailty
|
85 |
All |
18 Years and older (Adult, Older Adult) |
NCT01180075 |
09-2120
1K23AI093156-01A1 |
|
May 2010 |
August 2014 |
August 2014 |
August 11, 2010 |
December 2, 2014 |
|
- University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
|
|
| 14 |
NCT01177059 |
Completed |
Long Term Follow-Up Study of Human Immunodeficiency Virus Type 1 (HIV-1) Positive Patients Who Have Received OZ1 Gene Therapy as Part of a Clinical Trial |
|
- Genetic: OZ1 transduced cells
|
Interventional
|
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Adverse events, reportable events such as cancers and deaths
- Clonal expansion of cells with a predominant OZ1 insertion site
- Assess quantitative marking of the gene transfer product in peripheral blood mononuclear cells (PBMC) over time
|
68 |
All |
Child, Adult, Older Adult |
NCT01177059 |
CR016027
OZ1-HV1-202 |
|
December 6, 2004 |
November 30, 2017 |
November 30, 2017 |
August 6, 2010 |
May 30, 2018 |
|
- Los Angeles, California, United States
- San Francisco, California, United States
- New York, New York, United States
- (and 3 more...)
|
|
| 15 |
NCT01186575 |
Completed |
Text Messaging to Improve Adherence to Clinic Visits and Reduce Early Resumption of Sexual Intercourse After Male Circumcision |
- HIV Infections
- Acquired Immunodeficiency Syndrome
- Circumcision, Male
- (and 2 more...)
|
|
Interventional
|
Not Applicable |
- University of Washington
- University of Illinois at Chicago
- Kenya Medical Research Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Proportion of men failing to return for a post-operative clinic visit at 7 days.
- Proportion of men who report resumption of sexual activity before 42 days post-circumcision.
- Time to resumption of sex by study arm
- Correlates of failure to attend the scheduled 7-day post-operative visit
|
1200 |
Male |
18 Years and older (Adult, Older Adult) |
NCT01186575 |
38465-E/G |
|
August 2010 |
March 2011 |
June 2011 |
August 23, 2010 |
January 16, 2015 |
|
- Nyanza Reproductive Health Society
Kisumu, Nyanza, Kenya
|
|
| 16 |
NCT01383837 |
Completed |
HIV/STI Prevention for Adolescents With Substance Use Disorders in Treatment |
- HIV
- Sexually Transmitted Diseases
|
- Behavioral: STYLEnS
- Behavioral: Health Promotion
|
Interventional
|
Phase 1
Phase 2 |
- New York State Psychiatric Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Triple (Participant, Care Provider, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Unprotected vaginal or anal sex occasions
- Caregiver-youth communication about sex
- Caregiver-youth communication about sexual risk behaviors
- (and 2 more...)
|
86 |
All |
13 Years to 24 Years (Child, Adult) |
NCT01383837 |
6183/6622 |
STYLEnS |
August 2010 |
May 2015 |
August 2015 |
June 28, 2011 |
August 28, 2015 |
|
- St. Lukes-Roosevelt Hospital
New York, New York, United States
|
|
| 17 |
NCT01168167 |
Completed |
Impact of Raltegravir on HIV-1 cDNA Slope Following Antiretroviral Therapy (ART) Initiation |
|
|
Observational
|
|
- Christoph Stephan
- University Hospital Heidelberg
- Goethe University
|
Other |
- Observational Model: Case Control
- Time Perspective: Prospective
|
- Dynamical measurement of HIV-1 DNA-species extracted from whole blood-PBMCs
- CD4 cell counts
- plasma-HIV-1 RNA
|
20 |
All |
18 Years and older (Adult, Older Adult) |
NCT01168167 |
JWG-HIVCENTER-Hopp1 |
|
June 2010 |
March 2011 |
May 2012 |
July 23, 2010 |
March 23, 2016 |
|
- Johann Wolfgang Goethe-University Hospital
Frankfurt, Hessen, Germany
|
|
| 18 |
NCT01182298 |
Terminated
Has Results |
Open Label Study to Evaluate Chronic Hepatitis C Treatment in Latino Subjects With and Without HIV Co-infection |
|
|
Observational
|
|
- National Institute of Allergy and Infectious Diseases (NIAID)
- Fundación de Investigación de Diego
- National Institutes of Health Clinical Center (CC)
|
NIH / Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Median Log Change in HCV RNA Levels on Day 7
|
10 |
All |
18 Years and older (Adult, Older Adult) |
NCT01182298 |
100159
10-I-0159 |
LATHCV |
July 2010 |
March 2013 |
March 2013 |
August 16, 2010 |
October 2, 2014 |
October 2, 2014 |
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
|
| 19 |
NCT01192035 |
Completed |
PI or NNRTI as First-line Treatment of HIV in West Africa - the PIONA Trial |
|
- Drug: Efavirenz or Nevirapine
- Drug: Ritonavir-boosted lopinavir
|
Interventional
|
Phase 4 |
- University of Aarhus
- Aarhus University Hospital Skejby
- Bandim Health Project
- (and 2 more...)
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Fraction of patients with viral load suppression <400 copies/ml
- Fraction of patients with viral load suppression <50 copies/ml
- Increment of CD4+ cell count of at least 100 cells/µL
- (and 7 more...)
|
400 |
All |
18 Years and older (Adult, Older Adult) |
NCT01192035 |
11/CNES/2010 |
PIONA |
May 2011 |
September 2014 |
September 2014 |
August 31, 2010 |
June 25, 2015 |
|
- Centro de Tratamento Ambulatoria do Hospital Nacional Simão Mendes
Bissau, Guinea-Bissau
|
|
| 20 |
NCT01196468 |
Unknown † |
HIV Indicator Diseases Survey Across Europe - UK Arm |
- HIV
- AIDS
- Indicator Diseases/Indicator Conditions
|
- Other: HIV test (serological or salivary)
- Other: Interview
|
Observational
|
|
- Chelsea and Westminster NHS Foundation Trust
- HIV in Europe (Co-Sponsor)
|
Other |
- Time Perspective: Cross-Sectional
|
- Prevalence of HIV infection in patients presenting to specific services with specific HIV indicator diseases
- Previous HIV testing behaviour of individuals presenting with an indicator disease or condition (sub-study only)
- Demographic data of individuals presenting for care with specified indicator diseases
- (and 4 more...)
|
2000 |
All |
16 Years and older (Child, Adult, Older Adult) |
NCT01196468 |
Indicator Diseases Survey |
|
July 2010 |
July 2011 |
February 2014 |
September 8, 2010 |
April 12, 2012 |
|
- Chelsea and Westminster NHS Foundation Trust
London, United Kingdom - Royal Marsden NHS Foundation Trust
London, United Kingdom
|
|
| 21 |
NCT01176409 |
Completed |
Can Valacyclovir Attenuate Inflammation in Antiretroviral-Treated HIV-Infected Individuals With Herpes Simplex Virus Type 2? |
- Human Immunodeficiency Virus
- Herpes Simplex
|
- Drug: Valacyclovir
- Drug: Placebo
|
Interventional
|
Phase 3 |
- University Health Network, Toronto
- University of Toronto
- Canadian Institutes of Health Research (CIHR)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Percentage activated CD8+ T-cells
- Inflammatory markers
- CD4 cell count
- (and 4 more...)
|
60 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01176409 |
VALIANT-001 |
VALIANT Pilot |
September 2010 |
August 2013 |
August 2013 |
August 6, 2010 |
May 12, 2016 |
|
- Toronto General Hospital, University Health Network
Toronto, Ontario, Canada
|
|
| 22 |
NCT01170741 |
Completed |
Computer-Assisted Tailored Cue-card Health [CATCH] Study |
- Human Immunodeficiency Virus
- STDs
- Hepatitis, Viral, Human
|
- Behavioral: Tailored Cue Cards
|
Interventional
|
Phase 1 |
- RTI International
- National Institute on Drug Abuse (NIDA)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Prevention
|
|
122 |
All |
18 Years and older (Adult, Older Adult) |
NCT01170741 |
1R21DA026771 |
CATCH |
June 2010 |
June 2011 |
June 2012 |
July 27, 2010 |
October 25, 2012 |
|
- RTI International - Wake County Field Site
Raleigh, North Carolina, United States
|
|
| 23 |
NCT01173276 |
Terminated |
Intrauterine Insemination In HIV-Discordant Couples |
- HIV-1
- Fertility
- Infertility
|
- Other: Sperm Washing with Intrauterine Insemination (IUI)
|
Interventional
|
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Pregnancy
- Post-IUI HIV Infection of Female Subject
- Female Subject HIV-1/HIV-2 Serology
- Infant HIV-1/HIV-2 Serology
|
10 |
All |
18 Years to 50 Years (Adult) |
NCT01173276 |
ARTEMIS |
ARTEMIS |
September 2009 |
September 2012 |
October 2013 |
August 2, 2010 |
February 22, 2016 |
|
- Boston Medical Center
Boston, Massachusetts, United States
|
|
| 24 |
NCT01174654 |
Completed |
Development of a Methamphetamine Early Intervention |
- HIV
- Sexual Behavior
- Methamphetamine
- Behavioral Research
|
- Behavioral: Contingency management
|
Interventional
|
Phase 1
Phase 2 |
- University of Washington
- National Institute on Drug Abuse (NIDA)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Prevention
|
- Non-concordant unprotected anal intercourse
- Number of non-concordant unprotected anal intercourse partners
- Stimulant (methamphetamine and crack/cocaine) urinalyses
- Self-reported methamphetamine use
|
127 |
Male |
18 Years and older (Adult, Older Adult) |
NCT01174654 |
R21DA019420-01A1 |
|
December 2006 |
April 2009 |
April 2009 |
August 3, 2010 |
December 13, 2012 |
|
- Lifelong AIDS Alliance
Seattle, Washington, United States
|
|
| 25 |
NCT01213810 |
Withdrawn |
Prevention of Varicella Zoster Virus (VZV)-Reactivation in HIV-positive Individuals Enrolled in a Prospective Immunogenicity and Safety Trial of VZV Vaccine: PROVE-IT-Study |
|
|
Interventional
|
Phase 1
Phase 2 |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Prevention
|
|
0 |
All |
18 Years and older (Adult, Older Adult) |
NCT01213810 |
SHCS 610 |
|
December 2010 |
December 2011 |
June 2012 |
October 4, 2010 |
March 1, 2013 |
|
|
|
Create an RSS feed from your search for:
Download the search results for: